The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects

Inclusion Criteria:

- Age 18-65 years inclusive at the time of consent. The date of signing informed
consent is defined as the beginning of the Screening Period. This inclusion criterion
will only be assessed at the Screening Visit.

- Subject is considered "healthy". Healthy status is defined by absence of evidence of
any active or chronic disease following a detailed medical and surgical history, a
complete physical examination including vital signs, 12-lead ECG, hematology, blood
chemistry, and urinalysis.

- Serum ferritin >20ng/mL, hemoglobin >125g/l, and erythrocyte indices within normal
range of the clinical laboratory at the Screening Visit and on Day -1: packed cell
volume, mean corpuscular volume, and mean corpuscular hemoglobin concentration, or
deemed not clinically significant by the investigator.

- Subject is willing to comply with any applicable contraceptive requirements of the
protocol and is:

- Male, or

- Female of non-childbearing potential (defined as a female who is post-menopausal
[amenorrhea for at least 12 consecutive months] or surgically sterile [hysterectomy,
bilateral tubal ligation, bilateral oophorectomy, or bilateral salpingectomy]) and at
least 6 weeks post-sterilization

- Non-pregnant, non-lactating female

- At least 90 days post-partum or nulliparous (females only).

- An understanding, ability, and willingness to fully comply with study procedures and
restrictions.

- Ability to provide written, personally signed, and dated informed consent to
participate in the study, in accordance with International Conference on
Harmonisation Good Clinical Practice Guideline E6 (1996) and applicable regulations,
before completing any study-related procedures.

- Body mass index between 18.5-30.0kg/m² inclusive. This inclusion criterion will be
assessed only at the Screening Visit.

- Ability to swallow the investigational product (multiple capsules at 1 time or
consecutively 1 capsule at a time).

Exclusion Criteria:

- A clinically significant history or disorder detected during the medical
interview/physical examination such as any cardiovascular, bronchopulmonary,
gastrointestinal (eg, inflammatory bowel disease, chronic diarrhea), hepatic, biliary
(including gall bladder removal), renal, hematological, endocrine, autoimmune,
neurological, or psychiatric disease (including depression) or any other medical
condition that is capable of altering the absorption, metabolism, or elimination of
drugs; or of constituting a risk factor when taking the investigational product in
the judgment of the investigator.

- Confirmed systolic blood pressure >139mmHg or <89mmHg, and diastolic blood pressure
>89mmHg or <49mmHg.

- Twelve-lead ECG demonstrating QTc >450msec at screening. If QTc exceeds 450msec, the
ECG should be repeated 2 more times and the average of the 3 QTc values should be
used to determine the subject's eligibility.

- Subject reports any food allergies, celiac disease, or requirements for specific diet
(eg, vegan, vegetarian, low fat).

- Acute illness, as judged by the investigator, within 2 weeks of Day 1 of Treatment
Period 1.

- Known or suspected intolerance or hypersensitivity to the investigational products,
closely related compounds, or any of the stated ingredients.

- History of thyroid disorder that has not been stabilized on thyroid medication or
treatment within 3 months of the Screening Visit.

- History of alcohol or other substance abuse within the last year.

- Routine consumption of more than 3 units of caffeine per day or subjects who
experience caffeine withdrawal headaches.

- A positive screen for alcohol or drugs of abuse at the Screening Visit.

- Male subjects who consume more than 3 units of alcohol per day. Female subjects who
consume more than 2 units of alcohol per day.

- A positive human immunodeficiency virus antibody screen, hepatitis B surface antigen
screen, or hepatitis C virus antibody screen.

- Current use of any other medication (including over-the-counter, herbal, or
homeopathic preparations) that could affect (improve or worsen) the study evaluations
according to the investigator.

- Use of tobacco in any form (eg, smoking or chewing) or other nicotine-containing
products in any form (eg, gum, patch) within 30 days prior to Day 1 of Treatment
Period 1.

- Donation of blood or blood products (eg, plasma or platelets) within 60 days prior to
Day 1 of Treatment Period 1.

- Use of another investigational product within 30 days prior to Day 1 of Treatment
Period 1 or active enrollment in another drug or vaccine clinical study.

- Substantial changes in eating habits within 30 days prior to Day 1 of Treatment
Period 1, as assessed by the investigator.

- Prior screen failure, randomization, participation, or enrollment in this study.